Cardiovascular profile of loratadine
1999; Wiley; Volume: 29; Issue: S3 Linguagem: Inglês
10.1046/j.1365-2222.1999.0290s3197.x
ISSN1365-2222
AutoresJohn A. Hey, M B Affrime, Barton Cobert, William Kreutner, Francis M. Cuss,
Tópico(s)Ion Transport and Channel Regulation
ResumoThe extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre‐existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.
Referência(s)